Prognostic and Pathogenetic Implications of Immune Complexes in Human Cancer

  • F. A. Salinas
  • K. H. Wee
Part of the Advances in Immunity and Cancer Therapy book series (IMMUNITY, volume 2)


Serum markers for the diagnosis and monitoring of cancer have been demonstrated to be generally nonspecific (1). The evaluation of circulating immune complexes (CIC) has proven useful for following the clinical course of disease in cancer patients (2–8). High levels of CIC have been indicative of increased tumor burden and poor prognosis in malignant melanoma (9,10), breast carcinoma (11,12), ovarian carcinoma (13), neuroblastoma (14), gastrointestinal carcinoma (15), lung carcinoma (16), sarcoma (105), bone tumors (17), and leukemias (18). Initially, only tumor-associated antibodies were considered responsible for the immunomodulation observed in cancer patients, but currently tumor-associated immune complexes and their antigens have been demonstrated to have a major “blocking factors” role (19,20,54). Also, CIC have been shown to modulate tumoricidal activity of macrophages (21), natural killer (NK) cells (22), and antibody-dependent cytotoxicity (16,23).


Immune Complex Tumor Burden Circulate Immune Complex Fetal Liver Cell Oncofetal Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations used in text


Bacillus Calmette Guerin


circulating immune complexes


fetal liver cell


human oncofetal antigen


melanoma associated antigens


natural killer cells


normal control sera


polyethylene glycol




sodium dodecyl sulfate-polyacrylamide gel electrophoresis


sucrose gradient fractionation


xenogeneic oncofetal antigens


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Salinas FA, Wee KH, Silver HKB: Clinical relevance of immune complexes, associated antigen and antibody in cancer. In Salinas FA, Hanna MG (eds): Immune Complexes and Human Cancer, pp 55–109. New York: Plenum Press, 1985.Google Scholar
  2. 2.
    Mukojima T, Gunven P, Klein G: Circulating antigen-antibody complexes associated with Epstein-Barr virus in recurrent Burkitt’s lymphoma. J Natl Cancer Inst 51: 1319–1321, 1973.PubMedGoogle Scholar
  3. 3.
    Heimer R, Klein G: Circulating immune complexes in sera of patients with Burkitt’s lymphoma and nasopharyngeal carcinoma. Int J Cancer 18: 310–316, 1976.PubMedCrossRefGoogle Scholar
  4. 4.
    Rossen RD, Reisberg MA, Hersch EM, Gutterman JU: The Clq binding test for immune complexes: Clinical correlations obtained in patients with cancer. J Natl Cancer Inst 58: 1205–1215, 1977.PubMedGoogle Scholar
  5. 5.
    Samayoa EA, McDuffie FC, Nelson AM, Go VLW, Luthra SS, Brumfield HQ: Immunoglobulin complexes in serum of patients with malignancy. Int J Cancer 19: 12–16, 1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Theofilopoulos AN, Andrews BS, Urist MM, Morton DL, Dixon FJ: The nature of immune complexes in human cancer sera. J Immunol 119: 657–663, 1977.PubMedGoogle Scholar
  7. 7.
    Gupta RK, Golub SH, Morton DL: Correlation between tumor burden and anticomplementary activity in sera from cancer patients. Cancer Immunol Immunother 6: 63–71, 1979a.Google Scholar
  8. 8.
    Salinas FA, Wee KH, Silver HKB: Immune complexes and human neoplasia: Detection and quantitation of circulating immune complexes by the fetal liver cell assay. Cancer Immunol Immunother 12: 11–19, 1981a.CrossRefGoogle Scholar
  9. 9.
    Jerry LM, Rowden G, Cano PO: Immune complexes in human melanoma: A consequence of deranged immune regulation. Scand J Immunol 5: 845–859, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Kristensen E, Brandslund I, Nielsen H, Svehag SE: Prognostic value of assays for circulating immune complexes and natural cytotoxicity in malignant skin melanoma (stage I and II). Cancer Immunol Immunother 9: 31–36, 1980.CrossRefGoogle Scholar
  11. 11.
    Höffken K, Meredith ID, Robins RA, Baldwin RW, Davies CJ, Blamery RW: Immune complexes and prognosis of human breast cancer. Br Med J 2: 218, 1978.CrossRefGoogle Scholar
  12. 12.
    Höffken K, Meredith ID, Robins RA, Baldwin RW, Davies CJ, Blarney RW: Circulating immune complexes in patients with breast cancer. Br Med J 2: 218–220, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Poulton TA, Crowther ME, Hay FC, Nineham LJ: Immune complexes in ovarian cancer. Lancet 2: 72–73, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Brandeis WE, Helson L, Wang Y, Good RA, Day NK: Circulating immune complexes in sera of children with neuroblastoma: Correlation with stage of disease. J Clin Invest 62: 1201, 1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Staab HJ, Anderer FA, Stumpf E, Fischer R: Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract? Br J Cancer 42: 26–32, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    Gropp G, Havemann K, Scherfe T, Ax W: Incidence of circulating immune complexes in patients with lung cancer and their effect on antibody-dependent cytotoxicity. Oncology 37: 71–76, 1980.PubMedCrossRefGoogle Scholar
  17. 17.
    Eiras AS, Robins RA, Baldwin RW, Byers VS: Circulating immune complexes in patients with bone tumors. Int J Cancer 25: 735–739, 1980.PubMedCrossRefGoogle Scholar
  18. 18.
    Carpentier NA, Miescher PA: The clinical relevance of circulating immune complexes in cancer, kidney transplantation, and pregnancy. In Ray PK (ed): Immunobiology of Transplantation, Cancer and Pregnancy, pp 375–408. New York: Pergamon Press, 1983.Google Scholar
  19. 19.
    Baldwin RW, Robins RA: Factors interfering with immunological rejection of tumours. Br Med Bull 32: 118–123, 1976.PubMedGoogle Scholar
  20. 20.
    Hellström KE, Hellström I, Nepom JT: Specific blocking factors-are they important? Biochem Biophys Acta 473: 121–148, 1977.PubMedGoogle Scholar
  21. 21.
    Esparza I, Green R, Schreiber RD: Inhibition of macrophage tumoricidal activity by immune complexes and altered erythrocytes. J Immunol 131: 2117–2121, 1983.PubMedGoogle Scholar
  22. 22.
    Salinas FA, Wee KH, Silver HKB: Immunomodulation in cancer patients (pts): Humoral and cellular interactions. Workshop Presentation #506–07, Fifth Int Cong Immunol, Kyoto, Japan, 1983.Google Scholar
  23. 23.
    Miyama-Inaba M, Suzuki T, Paku YH, Masuda T: Feedback regulation of immune responses by immune complexes: Possible involvement of a suppressive lymphokine by FcRy-bearing B cell. J Immunol 128: 882–887, 1982.PubMedGoogle Scholar
  24. 24.
    Maidment BW Jr, Papsidero LD, Nemoto T, Chu TM: Recovery of immunologically reactive antibodies and antigens from breast cancer immune complexes by preparative isoelectric focusing. Cancer Res 41: 795–800, 1981.PubMedGoogle Scholar
  25. 25.
    Salinas FA, Wee KH, Silver HKB, Ragaz J: Circulating immune complexes and associated antigen in breast carcinoma. Proc Am Assoc Cancer Res 23: 250, 1982.Google Scholar
  26. 26.
    Salinas FA, Wee KH, Silver HKB: Detection of epithelial breast carcinoma associated antigen (BCAA) by monoclonal antibodies. Proc Am Soc Clin Oncol 2: 103, 1983.Google Scholar
  27. 27.
    Chu TM, Maidment BW Jr, Koestler TP, Papsidero LD, Inaji H, Croghan G, Killian CS, Loor RM, Douglass HO Jr, Berjian R, Nemoto T: Immune complexes and cancer. In Moisi RM, Hyun J (eds): Immunodiagnostics, pp 259–268. New York: Alan R Liss Inc, 1983.Google Scholar
  28. 28.
    Cronin WJ, Dorsett BH, loachim HL: Isolation of lung carcinoma-associated antibodies from immune complexes and production of heterologous antisera. Cancer Res 42: 292–300, 1982.PubMedGoogle Scholar
  29. 29.
    Salinas FA, Wee KH, Silver HKB: Tumor burden and its relationship to antigen, size and composition of immune complexes. In Peeters H (ed): Protides of the Biological Fluids, vol 31, pp 749–752. Oxford: Pergamon Press, 1984.Google Scholar
  30. 30.
    Gupta RK, Morton DL: Tumor antigens. In Ray PK (ed): Immunobiology of Transplantation, Cancer and Pregnancy, pp 113–147. New York: Pergamon Press, 1983.Google Scholar
  31. 31.
    Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121: 439–462, 1965.PubMedCrossRefGoogle Scholar
  32. 32.
    Tatarinov YS: Content of embryo-specific alpha globulin in fetal and neonatal sera adult humans with primary carcinoma of the liver. Fed Proc Transpl [Suppi] 25: 344–346, 1966.Google Scholar
  33. 33.
    Wada T, Anzai T, Yachi A, Sakamoto S: Incidence of three different fetal proteins in sera of patients with primary hepatoma. In Peeters H (ed): Protides of the Biological Fluids, vol. 18, pp 221–226. Oxford: Pergamon Press, 1970.Google Scholar
  34. 34.
    Trouillas P: Carcinofetal antigen in glial tumors. Lancet 2: 552, 1971.PubMedCrossRefGoogle Scholar
  35. 35.
    Salinas FA, Smith JA, Hanna MG Jr: Immunologic cross-reactivity of antigens common to tumor and fetal cells. Nature 240: 41–43, 1972.PubMedCrossRefGoogle Scholar
  36. 36.
    Irie RF, Irie K, Morton DL: A membrane antigen common to human cancer and fetal brain tissues. Cancer Res 36: 3510–3517, 1976.PubMedGoogle Scholar
  37. 37.
    Bara J, Burtin P: Mucus-associated gastrointestinal antigens in transitional mucosa adjacent to human colonic adenocarcinomas: Their “fetal-type” association. Br J Cancer 16: 1303–1310, 1980.Google Scholar
  38. 38.
    Levine GB, Mills PE Jr, Epstein WV: Circulating IgG globulin anti-IgG globulin complex in a patient with carcinoma of the lung and severe neuromyopathy. J Lab Clin Med 69: 749–757, 1967.PubMedGoogle Scholar
  39. 39.
    Jones PC, Sze LL, Liu PY, Morton DL, Irie RF: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66: 249–254, 1981.PubMedGoogle Scholar
  40. 40.
    Salinas FA, Wee KH, Silver HKB: Immune complexes and human neoplasia: review II. Biomed Pharmacother 37: 211–218, 1983.PubMedGoogle Scholar
  41. 41.
    Salinas FA, Wee KH, Silver HKB: Detection and characterization of antibodies to xenogeneic oncofetal antigen (XOFA) in human neoplasia. In Rosenberg SA (ed): Serologic Analysis of Human Cancer Antigens, pp 539–559, 665–667. New York: Academic Press, 1980.Google Scholar
  42. 42.
    Dippold WG, Lloyd KO, Houghton AN, Li LTC, Ikeda H, Oettgen HF, Old LJ: Human melanoma antigens defined by monoclonal antibodies. In Mitchell MS, Oettgen HF (eds): Hybridoma in Cancer Diagnosis and Treatment, pp 173–182. New York: Raven Press, 1982.Google Scholar
  43. 43.
    Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: Definition of six new antigenic systems with monoclonal antibodies. Proc Natl Acad Sci USA 77: 6114–6118, 1980.PubMedCrossRefGoogle Scholar
  44. 44.
    Kupchik HZ, Zurawski VR Jr, Hurrell JGR, Zamcheck N, Black PH: Monoclonal antibodies to carcinoembryonic antigen produced by somatic cell fusion. Cancer Res 41: 3306–3310, 1981.PubMedGoogle Scholar
  45. 45.
    Bhattacharya M, Chatterjee SK, Barlow JJ, Fuji H: Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas. Cancer Res 42: 1650–1654, 1982.PubMedGoogle Scholar
  46. 46.
    Khan A, Grammer S, Chang D, Hill NO, Miller J: Mouse monoclonal antibody (WIMN-1) against malignant melanoma. Cancer Res 43: 5868–5872, 1983.PubMedGoogle Scholar
  47. 47.
    Varki NM, Reisfeld RA, Walker LE: Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res 44: 681–687, 1984.PubMedGoogle Scholar
  48. 48.
    Silver HKB, Karim KA, Archibald EL, Salinas FA: Serum sialic acid and sialyltransferase as monitors of tumor burden in malignant melanoma patients. Cancer Res 39: 5036–5042, 1979.PubMedGoogle Scholar
  49. 49.
    Hay FC, Nineham LJ, Roitt IM: Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase Clq. Clin Exp Immunol 24: 396–400, 1976.PubMedGoogle Scholar
  50. 50.
    Krapf F, Renger D, Schedel I, Fricke M, Kemper A, Deicher H: Circulating immune complexes in malignant diseases: Increased detection rate by simultaneous use of three assay methods. Cancer Immunol Immunother 15: 138–143, 1983.PubMedCrossRefGoogle Scholar
  51. 51.
    Sztaba-Kania M, Jassem J, Piskorzynska M, Kondrat W: Circulating immune complexes in patients with melanoma. Neoplasm 28: 491–496, 1981.Google Scholar
  52. 52.
    Salinas FA, Wee KH, Silver HKB: Evaluation of circulating immune complexes (CIC) in malignant melanoma (MM). Proc Am Assoc Cancer Res 20: 49, 1979.Google Scholar
  53. 53.
    Salinas FA, Wee KH, Silver HKB: Correlation between xenogeneic oncofetal antigen (XOFA) and tumor burden in cancer patients. Proc VII Soc Oncodev Biol Med, Surrey, England, 1979, p 16.Google Scholar
  54. 54.
    Salinas FA, Wee KH: Immune complexes and human neoplasia. I. Biomed Pharmacother 36: 119–125, 1983.Google Scholar
  55. 55.
    Male D, Roitt IM: Analysis of the components of immune complexes. Mol Immunol 16: 197–203, 1979.PubMedCrossRefGoogle Scholar
  56. 56.
    Shetlar MR, Masters YF: Use of thymolsulfuric acid reaction for determination of carbohydrates in biological material. Anal Chem 29: 402–405, 1957.CrossRefGoogle Scholar
  57. 57.
    Salinas FA, Wee KH, Silver HKB: On the relationship of human oncofetal antigen (HOFA) to tumor burden in malignant melanoma (MM). Fed Proc 41: 553, 1982.Google Scholar
  58. 58.
    Salinas FA, Wee KH, Silver HKB: Immune reactants changes and their relationship to tumor burden in malignant melanoma. Proc Am Soc Clin Oncol 1: 35, 1982.Google Scholar
  59. 59.
    Salinas FA, Wee KH, Silver HKB: Clinical relevance of human oncofetal antigen (HOFA) as a marker of tumor burden. In Peeters H (ed): Protides of the Biological Fluids, vol 32, pp 779–782. Oxford: Pergamon Press, 1984.Google Scholar
  60. 60.
    Gupta RK, Theofilopoulos AN, Dixon FJ, Morton DL: Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol Immunother 6: 211, 1979.Google Scholar
  61. 61.
    Salinas FA, Wee KH, Silver HKB: Xenogeneic oncofetal antigen (XOFA) and its relationship with tumor burden in malignant melanoma (MM) patients’ sera. Proc Am Assoc Cancer Res 21: 225, 1980.Google Scholar
  62. 62.
    Gauci L, Carause J, Serrou B: Immune complexes in the context of the immune response in cancer patients. In Serrou B, Rosenfeld C (eds): Immune Complexes and Plasma Exchanges in Cancer Patients, pp 37–98. New York: Elsevier/North Holland Biomedical Press, 1981.Google Scholar
  63. 63.
    Theofilopoulos AN, Eisenberg RA, Dixon FJ: Isolation of circulating immune complexes using Raji cells, separation of antigens from immune complexes and production of antiserum. J Clin Invest 61: 1570–1581, 1978.PubMedCrossRefGoogle Scholar
  64. 64.
    Salinas FA, Wee KH, Silver HKB: Modulation of lymphocyte activation by plasmapheresis in advanced malignant melanoma. In Resch K (ed): Proceedings of Mechanisms of Lymphocyte Activation, p 4790. Amsterdam: Elsevier/North Holland, 1981.Google Scholar
  65. 65.
    Salinas FA, Wee KH, Silver HKB: Malignant melanoma tumor burden and its relationship to antigen concentration, size and composition of immune complexes. Proc Am Assoc Cancer Res 21: 181, 1981.Google Scholar
  66. 66.
    McCarthy D, Goddard DH, Holborow EJ, Horsfall AC, Mumford PA, Maini RN: The effect of IgG aggregate size and concentration on reactivity in immune complex assays. J Immunol Methods 47: 349–358, 1981.PubMedCrossRefGoogle Scholar
  67. 67.
    Poskitt PKF, Poskitt TR: The L1210 assay for immune complexes: Application in cancer patients and correlation with disease progress. Int J Cancer 24: 560–566, 1979.PubMedCrossRefGoogle Scholar
  68. 68.
    Dorval G, Pross H: Immune complexes in cancer. In Espinoza L, Osterland C (eds): Circulating Immune Complexes, pp 161–177. New York: Futura Publishing Co, 1983.Google Scholar
  69. 69.
    Salinas FA, Wee KH: Immunomodulation: Humoral and cellular interactions. In Proc XXth Int Hematol Cong, p 568. Buenos Aires, Argentina, 1984.Google Scholar
  70. 70.
    Ruell P, Murray E, McCarthy WH, Hersey P: Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma. Oncodev Biol Med 3: 1–12, 1982.PubMedGoogle Scholar
  71. 71.
    Gupta RK, Morton DL: Immunochemical characterization of fetal antigen isolated from spent culture medium of a human melanoma cell line. J Natl Cancer Inst 70: 993–1003, 1983.PubMedGoogle Scholar
  72. 72.
    Teshima H, Wanebo H, Pinsky C, Day NK: Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients. J Clin Invest 59: 1134–1142, 1977.PubMedCrossRefGoogle Scholar
  73. 73.
    Yoshida R, Zawadski ZA: Circulating immune complexes in patients with neoplastic disorders. Oncology 37: 152–156, 1980.PubMedCrossRefGoogle Scholar
  74. 74.
    Carpentier NA, Lange GT, Fiere DM: Clinical relevance of circulating immune complexes in human leukemia. J Clin Invest 60: 874–884, 1977.PubMedCrossRefGoogle Scholar
  75. 75.
    Dent PB, Louis JA, McCullough PB, Dunnett CW, Cerottini JC: Correlation of elevated Clq binding activity and carcinoembryonic antigen levels with clinical features and prognosis in bronchogenic carcinoma. Cancer 45: 130–136, 1980.PubMedCrossRefGoogle Scholar
  76. 76.
    Papsidero LD, Nemoto T, Snyderman MC, Chu TM: Immune complexes in breast cancer patients as detected by Clq binding. Cancer 44: 1636–1640, 1979.PubMedCrossRefGoogle Scholar
  77. 77.
    Carrel S, Accolla RS, Carmgnola AL, Mack JP: Common human melanoma-associated antigen(s) detected by monoclonal antibodies. Cancer Res 40: 2523–2528, 1980.PubMedGoogle Scholar
  78. 78.
    Moseley HL, Whaley K: Control of complement activation in membranous and membranoproliferative glomerulonephritis. Kidney Int 17: 535–544, 1980.PubMedCrossRefGoogle Scholar
  79. 79.
    Cochrane CG, Dixon FJ: Antigen-antibody complex induced disease. In Miescher PA, Muller-Eberhard HJ (eds): Textbook of Immunopathology, vol 1, pp 137–156. New York: Grune & Stratton, 1976.Google Scholar
  80. 80.
    Hughli TE, Muller-Eberhard HJ: Anaphylotoxins: C3a and C5a. Adv Immunol 26: 1–53, 1978.CrossRefGoogle Scholar
  81. 81.
    Miller GW, Nussenzweig V: A new complement function: Solubilization of antigen-antibody aggregates. Proc Natl Acad Sci USA 72: 418–422, 1975.PubMedCrossRefGoogle Scholar
  82. 82.
    Kazatchkine MD, Nydegger UE: The human alternative complement pathway: Biology and immunopathology of activation and regulation. Prog Allergy 30: 193–234, 1982.PubMedGoogle Scholar
  83. 83.
    Burnet FM: Immunological surveillance in neoplasia. Transplant Rev 1: 3–25, 1971.Google Scholar
  84. 84.
    Mathé G, Pouillart P: Active immunotherapy of L1210 leukemia applied after the graft of tumor cells. In Mathé G (ed): Advanced in the Treatment of Acute (Blastic) Leukemias. Recent Results in Cancer Research, pp 64–75. New York: Springer-Verlag, 1970.Google Scholar
  85. 85.
    Baldwin RW, Price MR, Robins RA: Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumor-specific antigen-antibody complexes. Nature 238: 185–187, 1972.CrossRefGoogle Scholar
  86. 86.
    Hellström KE, Hellström I: Lymphocyte mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18: 209–277, 1974.PubMedCrossRefGoogle Scholar
  87. 87.
    Bansal SC, Bansal BR, Boland JP: Blocking and unblocking serum factors in neoplasia. Current Topics Microbiol Immunol 75: 45–76, 1976.Google Scholar
  88. 88.
    Salinas FA, Silver HKB, Grossman L, Thomas JW: Plasmapheresis: A new approach in the management of advanced malignant melanoma. In Serrou B, Rosenfeld C (eds): Immune Complexes and Plasma Exchanges in Cancer Patients, vol 1, pp 253–270. Amsterdam: Elsevier/North Holland, 1981.Google Scholar
  89. 89.
    Bansal SC, Bansal BR, Thomas HL, Siegel PD, Rhoads JE, Cooper DR, Terman DS, Mark R: Ex-vivo removal of serum IgG in a patient with colon carcinoma. Cancer 42: 1–18, 1978.PubMedCrossRefGoogle Scholar
  90. 90.
    Ray PK, McLaughlin D, Mohamet J, Idiculla A, Rhoads JE, Mark R, Bassett JR, Cooper DR: Ex-vivo immunoadsorption of IgG or its complexes-a new modality of cancer treatment. In Serrou B, Rosenfeld C (eds): Immune Complexes and Plasma Exchanges in Cancer Patients, vol 1, pp 197–220. Amsterdam: Elsevier/North Holland, 1981.Google Scholar
  91. 91.
    Ray PK, Idiculla A, Mark R, Rhoads, JE, Thomas H, Bassett JG, Cooper DR: Extracorporeal immunoadsorption of plasma from a metastatic colon carcinoma patient by protein A-containing nonviable S. aureus. Cancer 49: 1800–1809, 1982.Google Scholar
  92. 92.
    Terman DS, Young JB, Shearer WT, Ayus CA, Lehane D, Mattioli C, Espada R, Howell JF, Yamamoto T, Zaleski HI, Miller L, Frommer P, Feldman L, Henry JF, Tillquist R, Cook G, Daskal Y: Preliminary observations of the effects on breast carcinoma of plasma perfused over immobilized protein A. N Engl J Med 305: 1195–1200, 1981.PubMedCrossRefGoogle Scholar
  93. 93.
    Jones FR, Grant CK, Snyder HW Jr: Lymphosarcoma and persistent FeLV infection of pet cats: A system to study responses during extracorporeal treatments. J Biol Resp Modific 3: 286–292, 1984.Google Scholar
  94. 94.
    Lodola MA, Villa ML, Masserini C, Clerici E• Immunocomplexes in normal blood donors and in melanoma patients. Immunol Leu 23: 27, 1981.Google Scholar
  95. 95.
    Köhler G, Milstein C: Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6: 511–519, 1976.PubMedCrossRefGoogle Scholar
  96. 96.
    Sobol RE, Dillman RO, Smith JD, Imai K, Ferrone S, Shawler D, Glassy MC, Royston I: Phase I evaluation of murine monoclonal anti-melanoma antibody in man: Preliminary observations. In Mitchell MS, Oettgen HF (eds): Hybridoma in Cancer Diagnosis and Treatment, pp 199–206. New York: Raven Press, 1982.Google Scholar
  97. 97.
    Larson SM, Carrasquillo JA, Krohn KA: Radiotherapy with “anti-p97” iodinated monoclonal antibodies in melanoma. In Raynaud C (ed): Proceedings of Third World Congress of Nuclear Medicine and Biology, vol 4, pp 3666–3669. New York: Perga-mon Press, 1982.Google Scholar
  98. 98.
    Embleton MJ, Rowland GF, Simmonds RG, Jacobs E, Marsden CH, Baldwin RW: Selective cytotoxicity against human tumor cells by a vindesine-monoclonal antibody conjugate. Br J Cancer 47: 43–49, 1983.PubMedCrossRefGoogle Scholar
  99. 99.
    Hashimoto Y, Sugawara M, Masuko T, Hojo H: Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody. Cancer Res 43: 5328–5334, 1983.PubMedGoogle Scholar
  100. 100.
    Kishida K, Masuho Y, Saito M, Hara T, Fuji H: Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity. Cancer Immunol Immunother 16:93–97, 1983.Google Scholar
  101. 101.
    Bast RC Jr, Ritz J, Lipton JM, Feeney M, Sallan SE, Nathan DG, Schlossman SF: Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43: 1389–1394, 1983.PubMedGoogle Scholar
  102. 102.
    Oldham RK: Monoclonal antibodies in cancer therapy. J Clin Oncol 1: 582–590, 1983.PubMedGoogle Scholar
  103. 103.
    Lambert PH, Dixon FJ, Zubler RH, Agnello V, Cambiaso C, Casali P, Clarke J, Cowdery JS, McDuffie FC, Hay FC, MacLennan ICM, Masson P, Müller-Eberhard HJ, Penttinen K, Smith M, Tappeiner G, Theofilopoulos AN, Verroust P: A WHO collaborative study for the evaluation of eighteen methods for detecting immune complexes in serum. J Clin Lab Immunol 1: 1–15, 1978.Google Scholar
  104. 104.
    Perrin LH, Lambert PH, Miescher PA: Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 56: 165–176, 1975.PubMedCrossRefGoogle Scholar
  105. 105.
    Salinas FA, Weir ER, Wee KH: Antigenic heterogeneity as reflected by interaction with antibody (Ab) and circulating immune complexes (CIC) in sarcoma patients. In Peeters H (ed): Protides of the Biological Fluids, vol 33, pp 373–376. Oxford: Pergamon Press, 1985.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1986

Authors and Affiliations

  • F. A. Salinas
  • K. H. Wee

There are no affiliations available

Personalised recommendations